Myriad Genetics Inc. filings document the regulatory record of a molecular diagnostics and precision medicine company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue and test-volume information, guidance, and product-related operating updates tied to Cancer Care Continuum, Prenatal Health, Mental Health, Precise MRD, and MyChoice CDx.
The company's proxy materials cover board matters, executive compensation, equity awards, and annual meeting governance. Other current reports document officer transitions, compensatory arrangements, and amendments to previously furnished earnings materials, providing formal disclosure of governance changes and financial-reporting corrections.
Myriad Genetics director S. Louise Phanstiel reported open‑market purchases of a total of 104,507 shares of common stock across three days. She bought 6,100 shares on February 25 at $4.736 per share, 50,407 shares on February 26 at $4.803 per share, and 48,000 shares on February 27 at $4.661 per share.
The reported prices are weighted averages for multiple trades executed within disclosed intraday ranges. After these transactions, she held 281,951 shares directly and 33,119 shares indirectly through The Phanstiel Trust.
Myriad Genetics is registering up to $200,000,000 of securities for sale from time to time. This shelf prospectus, dated February 24, 2026, covers common stock, preferred stock, depositary shares, debt securities and warrants that the company may offer in one or more offerings.
The prospectus explains that specific terms, prices and underwriting arrangements will be provided in future prospectus supplements, and that proceeds from any sales are expected to be used for general corporate purposes, including operations, R&D, possible debt repayment and acquisitions.
Myriad Genetics outlines its 2025 business strategy and operations in oncology, women’s health, and mental health, centered on molecular diagnostics and precision medicine. The company emphasizes hereditary cancer testing, prenatal screening, and the GeneSight pharmacogenomic test for psychiatric medications.
Growth priorities include building a comprehensive Cancer Care Continuum portfolio, expanding Precise MRD for molecular residual disease, and launching the FirstGene 4‑in‑1 prenatal screen in 2026. Myriad highlights collaborations with PATHOMIQ and SOPHiA GENETICS, strong customer satisfaction (Net Promoter Score above 70), and significant R&D investment of $106.8 million in 2025.
The report notes competition from major diagnostic players, dependence on payer reimbursement, evolving FDA, CLIA, EU and UK regulation, and extensive IP and licensing arrangements. As of June 30, 2025, non‑affiliate market value was $494,049,876, and as of February 19, 2026, there were 93,508,165 shares outstanding and about 2,700 employees.
Myriad Genetics reported fourth quarter 2025 revenue of $209.8 million, essentially flat year-over-year, with a GAAP net loss of $7.9 million, or $0.08 per share. On a non-GAAP basis, adjusted EPS was $0.04 and adjusted EBITDA was $14.3 million, reflecting lower operating expenses.
For full-year 2025, revenue was $824.5 million, down 2%, and the company recorded a GAAP net loss of $365.9 million, driven largely by $319.4 million of goodwill and long-lived asset impairments. Cash and cash equivalents were $149.6 million at December 31, 2025. Myriad reaffirmed 2026 guidance, targeting revenue of $860–$880 million, adjusted gross margin of 68–69%, and adjusted EBITDA of $37–$49 million, with Q1 2026 revenue expected between $200 and $203 million.
Myriad Genetics, Inc. received an amended Schedule 13G filing showing that funds associated with Millennium now report a sizable passive stake in its common stock. Integrated Core Strategies (US) LLC reports beneficial ownership of 5,183,588 shares, representing 5.6% of the outstanding common stock.
Affiliates Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report beneficial ownership of 6,700,158 shares, or 7.2% of the class, with shared voting and dispositive power. The filing is certified as a passive investment, stating the securities were not acquired to change or influence control of Myriad Genetics.
State Street Corporation filed a Schedule 13G reporting a passive ownership stake in Myriad Genetics, Inc. common stock as of 12/31/2025. State Street reports beneficial ownership of 5,966,567 shares, representing 6.4% of Myriad Genetics’ outstanding common stock.
The filing shows State Street has shared voting power over 5,683,556 shares and shared dispositive power over 5,966,567 shares, with no sole voting or dispositive power. State Street certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Myriad Genetics.
Myriad Genetics reported an equity award to its Chief Financial Officer, Benjamin Richard Wheeler. On February 2, 2026, he acquired 4,994 shares of common stock at $0 per share, linked to previously granted performance-based restricted stock units (PSUs). These PSUs were originally granted on March 15, 2023, and the Compensation and Human Capital Committee set the final award amount based on performance metrics. Each PSU converts into one share of common stock and will vest on March 15, 2026. After this transaction, Wheeler beneficially owned 97,624 shares directly.
Myriad Genetics Chief Operating Officer Mark Verratti reported an award of common stock tied to earlier performance-based restricted stock units. On February 2, 2026, he acquired 32,810 shares of common stock at $0 per share, following certification of performance goals. After this award, he beneficially owned 414,636 shares directly. The underlying performance-based units were originally granted on March 15, 2023 and are scheduled to vest on March 15, 2026, with each unit representing one share of common stock.
Myriad Genetics reported that its Chief Scientific Officer, Dale Muzzey, received an award of 23,697 shares of common stock on February 2, 2026, at a price of $0 per share, increasing his directly held stake to 193,878 shares.
The shares relate to performance-based restricted stock units initially granted on March 15, 2023. The board’s Compensation and Human Capital Committee determined the final award amount based on pre-set performance metrics, and each unit will convert into one share of common stock vesting on March 15, 2026.
Myriad Genetics Chief Technology Officer Kevin Richard Haas reported an acquisition of 23,697 shares of common stock of the company on February 2, 2026 at a price of $0 per share. These shares relate to performance-based restricted stock units (PSUs) that were initially granted on March 15, 2023, with the final award amount determined by the board’s Compensation and Human Capital Committee based on preset performance metrics.
Each PSU represents a right to receive one share of Myriad Genetics common stock and is scheduled to vest on March 15, 2026. After this award, Haas beneficially owns 202,332 shares of Myriad Genetics common stock held directly.